KTTA | tickerfilter.com

Fundamental analysis

14%

Profitability 6%

Dept financing 2%

Liquidity 75%

Performance 10%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

4.89%

1 Month

-3.79%

3 Months

-54.19%

6 Months

-46.96%

1 Year

-65.98%

2 Year

-74.86%

Key data

Stock price

$2.79

P/E Ratio

-0.30

DAY RANGE

$2.57 - $2.88

EPS

-$0.61

52 WEEK RANGE

$2.66 - $9.25

52 WEEK CHANGE

-$62.30

MARKET CAP

4.752 M

YIELD

N/A

SHARES OUTSTANDING

1.044 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$28,296

AVERAGE 30 VOLUME

$23,285

Company detail

CEO: Tiago R. Marques
Region: US
Website: pasithea.com
Employees: 3
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Pasithea Therapeutics Corp. engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine.

KTTA - Pasithea Therapeutics Corp.